In vitro assay of the biological activity of bisphosphonates

• Autorzy: Chmielewska E. , Miszczyk P. , Kafarski P. , Kempińska K. , Wietrzyk J.
• Języki publikacji: EN

Abstrakty

EN

Nowadays, the use of bisphosphonates are the gold standard of treatment of bone diseases. Due to the high utility of these compounds, scientists still search for better and better structures, with a variety of substituents at carbon’s atom and create new libraries or improve methods of their synthesis. To determine the potential effect of newly discovered bisphosphonates, for example antiosteoporotic activity, there are in vitro tests which allow to determine the half maximal inhibitory concentrations (IC50) of cells. This paper describes in detail the methodology for test the biological activity of bisphosphonates. Shows the results of biological activity for synthesized bisphosphonates in relation to the commercial-incadronate and zoledronate.

Słowa kluczowe

EN

bisphosphonates; cytotoxicity; in vitro; biological activity; inhibitor

PL

bisfosfoniany; cytotoksyczność; in vitro; aktywność biologiczna; inhibitor

• Wydawca: Oficyna Wydawnicza Politechniki Wrocławskiej
• Czasopismo: Interdisciplinary Journal of Engineering Sciences
• Rocznik: 2014
• Tom: Vol. 2, no. 1
• Strony: 13--16
• Opis fizyczny: Bibliogr. 14 poz., rys.

Twórcy

autor

Chmielewska E.

• Wroclaw University of Technology, Poland

autor

Miszczyk P.

• Wroclaw University of Technology, Poland

autor

Kafarski P.

• Wroclaw University of Technology, Poland

autor

Kempińska K.

• L. Hirszfeld Institute of Immunology and Experimental Therapy Polish Academy of Science

autor

Wietrzyk J.

• L. Hirszfeld Institute of Immunology and Experimental Therapy Polish Academy of Science

Bibliografia

• [1] Fleisch, H., 1987, and Experimental Basis. In: Bone, 8, 23-28.
• [2] Fleisch, H., Russell, R. G. G., 1976, Pyrophosphate and Diphosphonates. Biochemistry and Physiology of Bone, 4, Bourn, G. H. (ed.), New York, Acad. Press. Inc.
• [3] Whitaker, M., Guo, J., Kehoe, T., Benson, G., 2012, we go from here? IN: New Engl. J. Med 366, 2048-2051
• [4] Green, J. R., 2003, Antitumor Effects of Bisphosphonates. In: Am. Canc. Soc., 97, Bethesda, Maryland, 840
• [5] Bisaz, S., Fleisch, H., Jung, A., 1973, The Binding of Phyrophosphate and Two Diphosphonates by Hydroxyapatite Crystals. In. Calc. Tiss. Res., 11, 269-280.
• [6] Fleisch, H., 1997, Mechanism of Action of the Bisphosphonates in Paget’s Desease of Bone. In: Medicina, 57, 65-75.
• [7] Russell, R. G. G., Watts, N. B., Ebetino, F. H., Rogers, M. J., 2008, Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. In: Osteoporos. Int., 19, 733-759.
• [8] Roelofs, A. J., Thompson, K., Ebetino, F. H., Rogers, M. J., Coxon, F. P., 2010, Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. In: Curr. Pharm. Des. 16, 2950-2960
• [9] Skehan, P., 1990, New calorimetric cytotoxicity of assay for anticancer In: J. Natl. Cancer Inst., 82, 1107-1112.
• [10] Blackburn, G. M., Brown, R. J., Carran, J., Hounslow, A. M., Rejman, D., Watts, D. J., 2008, Determination of the Microscopic Equilibrium Dissociation Constants for Risedronate and Its Analogues Reveals Two Distinc Roles for the Nitrogen Atom in Nitrogen Containing Bisphosphonate Drugs. In: J. . Med. Chem., 51, 4170-4178.
• [11] Li, C., Mori, S., Li, J., Kaji, Y., Akiyama, T., Kawanishi, J., Norimatsu, H., 2001, Long-Term Effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. In: J. Bone Miner. Res., 16, 429-436.
• [12] Mashida, T., Tanizawa, T., Takahashi, H. E., Takano, Y., Nishido, S., Mori, S., Norimatsu, H., 1995, Effects of single and concurrent intermittent administration of human parathyroid hormone and bisphosphonate cimadronate on bonemineral densities of femur in ovariectomized rats. In: J. Bone Miner. Res., 13, 17-22.
• [13] Nishikawa, N., Yamamoto, M., Murakami, T., Akatsu, T., Kugai, N., Nagata, N., 1998, A thirdgeneration bisphosphonate, YM175, inhibits osteoclast formation in murine cocultures by inhibiting proliferation of precursor cells via supporting cell-dependent mechanisms. In: J. Bone Miner. Res., 13, 986-995.
• [14] Geran, R. I., Greenberg, N. H., MacDonald, M. M., Schimacher, A. M., Abbott, B. J., 1972, Protocols for screening chemical agents and natural products against animal tumors and other biological systems, Cancer Chemotherapy Reports 3, 3(2), 1-17, 59-61.